Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zybrestat – Vascular Disrupting Agent and Cancer Therapy

Drug (Brand/Generic)

Zybrestat (combretastatin A4 phosphate)

Company/Licensee

Oxigene

Therapy Class

VDA

Product Description

Prodrug designed to destroy tumour blood supply

Current Indication

anaplastic thyroid cancer

Market Sector

Oncology

Development Status

Phase II/III
Expand

Go Top